ISSN: 2381-8727



当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い

700 ジャーナル 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得


High Riskof Acute Exacerbation ofInterstitial Lung Disease In Relapsed Small Cell Lung Cancer Treated With Amrubicin

Niwa H

Lung cancer is the leading cause of death from cancer worldwide. Small cell lung cancer (SCLC) accounts for 15% to 20% of lung cancer. SCLC is characterized by a high rate of invasion and rapid cell proliferation. The SCLC also shows a high sensitivity to chemotherapy and radiotherapy; however, the duration of the response is relatively short. The standard chemotherapy regimen for SCLC patients is a combination of platinum and etoposide agents or platinum agents plus irinotecan, which is the most frequently used combination and gives a median survival period of approximately 9 to 12 months in clinical trials. Interstitial lung disease (ILD) is characterized by damage to the lung parenchyma through inflammation and fibrosis. Preexisting ILD is a risk factor for acute exacerbation (AE) for chemotherapy-related ILD (AEILD). AE- ILD can cause death. Chemotherapy is possible for patients with SCLC with ILD remains unclear, since patients with ILD have been excluded from most prospective clinical trials. In clinical practice, patients with SCLC with ILD have been carefully treated with cytotoxic chemotherapy. Patients with advanced SCLC with ILD treated with etoposide and chemotherapy .